BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23511711)

  • 1. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
    Halama B; Hohmann N; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2013 Jun; 93(6):564-71. PubMed ID: 23511711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
    Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
    Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B; Mao J; Chien JY; Hall SD
    Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
    Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
    Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
    Chung E; Nafziger AN; Kazierad DJ; Bertino JS
    Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
    Stoch SA; Friedman E; Maes A; Yee K; Xu Y; Larson P; Fitzgerald M; Chodakewitz J; Wagner JA
    J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
    Greenblatt DJ; Peters DE; Oleson LE; Harmatz JS; MacNab MW; Berkowitz N; Zinny MA; Court MH
    Br J Clin Pharmacol; 2009 Dec; 68(6):920-7. PubMed ID: 20002087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Friedman EJ; Fraser IP; Wang YH; Bergman AJ; Li CC; Larson PJ; Chodakewitz J; Wagner JA; Stoch SA
    J Clin Pharmacol; 2011 Nov; 51(11):1561-70. PubMed ID: 21209240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
    Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
    Vuppugalla R; Zhang Y; Chang S; Rodrigues AD; Marathe PH
    Xenobiotica; 2012 Nov; 42(11):1058-68. PubMed ID: 22574883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.
    KuKanich B; Hubin M
    J Vet Pharmacol Ther; 2010 Feb; 33(1):42-9. PubMed ID: 20444024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
    Li WL; Xin HW; Su MW
    Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.